TI
ITCI

Trexquant Investment’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Trexquant Investment’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,585
Closed -$4.39M – 1935
2024
Q4 		$4.39M Sell
52,585
-46,964
-47% -$3.86M 0.05% 570
2024
Q3 		$7.28M Buy
99,549
+21,012
+27% +$1.58M 0.09% 333
2024
Q2 		$5.38M Buy
78,537
+6,089
+8% +$422K 0.08% 383
2024
Q1 		$5.01M Sell
72,448
-6,428
-8% -$442K 0.1% 296
2023
Q4 		$5.65M Buy
78,876
+3,035
+4% +$175K 0.13% 215
2023
Q3 		$3.95M Buy
75,841
+31,255
+70% +$1.82M 0.1% 291
2023
Q2 		$2.82M Buy
44,586
+11,693
+36% +$729K 0.07% 381
2023
Q1 		$1.78M Buy
32,893
+169
+0.5% +$8.17K 0.05% 501
2022
Q4 		$1.73M Buy
+32,724
New +$1.64M 0.05% 457
2022
Q3 		– Sell
-8,360
Closed -$477K – 1911
2022
Q2 		$477K Buy
+8,360
New +$474K 0.02% 851
2021
Q3 		– Sell
-15,366
Closed -$627K – 1560
2021
Q2 		$627K Buy
+15,366
New +$568K 0.05% 420
2020
Q2 		– Sell
-39,986
Closed -$615K – 1553
2020
Q1 		$615K Buy
+39,986
New +$868K 0.04% 589
2019
Q4 		– Sell
-18,383
Closed -$137K – 1307
2019
Q3 		$137K Buy
+18,383
New +$176K 0.01% 792
2018
Q3 		– Sell
-14,096
Closed -$249K – 1240
2018
Q2 		$249K Sell
14,096
-3,684
-21% -$74.8K 0.02% 733
2018
Q1 		$374K Sell
17,780
-19,423
-52% -$378K 0.03% 729
2017
Q4 		$539K Buy
37,203
+5,027
+16% +$77.6K 0.06% 482
2017
Q3 		$508K Buy
+32,176
New +$472K 0.13% 266
2017
Q2 		– Sell
-23,652
Closed -$384K – 1236
2017
Q1 		$384K Buy
+23,652
New +$342K 0.05% 647
2016
Q3 		– Sell
-8,581
Closed -$333K – 1052
2016
Q2 		$333K Buy
+8,581
New +$308K 0.04% 632
2015
Q3 		– Sell
-21,200
Closed -$677K – 1307
2015
Q2 		$677K Buy
+21,200
New +$538K 0.08% 499

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Trexquant Investment's ITCI Position: Q1 2025 in Review

Trexquant Investment sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 52,585 shares — an estimated $4.39M sold.

Trexquant Investment first reported a position in ITCI in Q2 2015 and held it in 20 quarters. The position peaked at $7.28M in Q3 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Trexquant Investment reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Trexquant Investment sold 52,585 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $4.39M.
  • Trexquant Investment first reported a position in Intra-Cellular Therapies Inc. in Q2 2015 and held it in 20 quarters.
  • Trexquant Investment's Intra-Cellular Therapies Inc. position peaked at $7.28M in Q3 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Trexquant Investment's 13F filing for Q1 2025, filed 14 May 2025.